Scientists Alvin Lo and Han Remaut of Vrije Universiteit Brussel (VIB) have identified a chemical substance with the potential of acting as a new drug to treat bacterial infections, particularly urinary tract infections. In contrast to the most popular antibiotics, this candidate drug does not destroy pathogenic bacteria, but rather disarms them. The benefit of this new strategy is that other (useful) bacteria are unharmed and there is a lower risk of the development and spread of resistance by bacteria.
As Remaut notes, "It gives great satisfaction to see that years of fundamental research can result in a new strategy for the treatment of bacterial infections. Instead of killing the pathogenic bacteria, we have disarmed them; an approach with possible benefits compared to the current antibiotics."
Many pathogenic bacteria attach to a cell before they can infect it, usually in a very similar manner. The research group led by Remaut has focused on a new approach in combating infections, which has succeeded in inhibiting this crucial step and thereby disarming the bacteria. In this case, they took aim at the bacterium that causes almost 80Â percent of urinary tract infections: the uropathogenic E. coli.
In order to prevent themselves being flushed out in the urine, E. coli bacteria attach themselves with the aid of hair-like structures -- type 1 pili. In 2011, Remaut and colleagues were the first to describe the pilus formation mechanism. Further research was necessary to translate these important structural insights into possible new drugs.
Lo and colleagues from Remaut's group started screening databases of chemical components in search of chemical molecules that could inhibit pilus formation. This yielded an inhibitor that interferes with an essential step in the assembly process of the pili. As a test, they exposed E. coli bacteria to this component, resulting in the bacteria no longer being able to produce pili. These "naked" bacteria were no longer able to attach to their host.
"E. coli is not the only pathogenic bacterium that uses this mechanism for attachment," Lo says. "If further research reveals that our molecule does indeed efficiently combat urinary tract infections, then we can also use this strategy in the fight against other infectious diseases such as food poisoning or traveler's diarrhea."
Source: Vrije Universiteit Brussel
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.